DNV3837 antibiotic candidate: the Phase II trial continues in the US
July 15, 2020 12:30 ET
|
Deinove
DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak DEINOVE (Euronext Growth Paris: ALDEI), a French biotech...
Alexis RIDEAU appointed Chief Executive Officer of DEINOVE with the ambition to strengthen the Company's strategy for innovation and partnerships
May 04, 2020 01:32 ET
|
Deinove
Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences field, particularly in microbiology applied to health and...
Official launch of Luminity®, DEINOVE's new cosmetic active ingredient for a radiant complexion
April 23, 2020 12:30 ET
|
Deinove
Luminity® is a concentrate of neurosporene, an extremely rare carotenoid that contributes to skin vitality and a beautiful complexion. Clinical tests have confirmed its ability to boost...
DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance
March 11, 2020 13:00 ET
|
Deinove
DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance The AGIR program, supported by the French Investments for the Future program, aims to accelerate new...
DEINOVE étoffe sa gamme commerciale d’ingrédientscosmétiques
February 19, 2020 12:30 ET
|
Deinove
DEINOVE étoffe sa gamme commerciale d’ingrédients cosmétiques Son deuxième caroténoïde innovant présente notamment la particularité d’absorber la lumière bleue, responsable du vieillissement...
DEINOVE expands its range of cosmetic active ingredients
February 19, 2020 12:30 ET
|
Deinove
DEINOVE expands its range of cosmetic active ingredients Its second innovative carotenoid has the particularity of absorbing blue light, which is responsible for premature skin ageing, the appearance...
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections
January 27, 2020 01:30 ET
|
Deinove
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837...
New industrial-scale production of Phyt-N-Resist® to supply the market
January 22, 2020 12:30 ET
|
Deinove
New industrial-scale production of Phyt-N-Resist® to supply the market DEINOVE launches the production of a new batch of Phyt-N-Resist® to meet the needs of its distributors and future...
DEINOVE et l’ESPCI Paris obtiennent un financement de l’ANR pour développer la technologie Deinodrop
December 09, 2019 12:30 ET
|
Deinove
DEINOVE et l’ESPCI Paris obtiennent un financement de l’ANR pour développer la technologie Deinodrop La technologie Deinodrop sera codéveloppée par l’ESPCI et DEINOVE pour accélérer la...
DEINOVE and ESPCI Paris obtain funding from the ANR to develop the Deinodrop technology
December 09, 2019 12:30 ET
|
Deinove
DEINOVE et l’ESPCI Paris obtiennent un financement de l’ANR pour développer la technologie Deinodrop La technologie Deinodrop sera codéveloppée par l’ESPCI et DEINOVE pour accélérer la...